Matching articles for "lorcaserin"
Diet, Drugs, Devices, and Surgery for Weight Management
The Medical Letter on Drugs and Therapeutics • June 4, 2018; (Issue 1548)
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs are FDA-approved
for weight reduction and maintenance (see
Table 1), and procedures such as endoscopic
placement of dilated balloons have produced beneficial
short-term results (see Table 2), but bariatric
surgery has been the most effective intervention for
sustainable long-term weight loss and reduction of
obesity-related comorbidities.
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • June 4, 2018; (Issue 1548)
...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Liraglutide (Saxenda) for Weight Loss
The Medical Letter on Drugs and Therapeutics • June 22, 2015; (Issue 1471)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as Saxenda
(Novo Nordisk) for chronic weight management
in adults with a BMI ≥30, or a BMI ≥27 with a
weight-related comorbidity such as hypertension,
dyslipidemia, or diabetes.
Diet, Drugs, and Surgery for Weight Loss
The Medical Letter on Drugs and Therapeutics • February 16, 2015; (Issue 1462)
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity...
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity can prevent some of the complications
of obesity, particularly type 2 diabetes. Diet and
exercise are the preferred methods for losing weight,
but long-term failure rates are high. Several drugs
have been approved by the FDA for weight reduction,
but adherence is poor, adverse effects are common,
and patients usually regain the lost weight when
the drug is stopped. Bariatric surgery can produce
substantial weight loss and significantly reduce
obesity-related comorbidities; long-term data on its
safety are encouraging, but still limited. Guidelines
for the management of overweight or obese adults
have recently been published.
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
The Medical Letter on Drugs and Therapeutics • November 10, 2014; (Issue 1455)
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and...
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and others),
as Contrave (Orexigen/Takeda) for weight loss. The
combination was approved for use as an adjunct to
diet and increased physical activity in patients with a
body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2
and one or more weight-related comorbidities such as
hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled substance.
Two Drugs for Weight Loss
The Medical Letter on Drugs and Therapeutics • September 3, 2012; (Issue 1398)
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective...
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m2) and for patients who are overweight (BMI ≥27 kg/m2) and have one weight-related risk factor such as hypertension, dyslipidemia or type 2 diabetes.